Knight Therapeutics Inc. (TSX:GUD)
Canada · Delayed Price · Currency is CAD 9.32
+0.11 (1.19%)
Aug 14, 2026, 4:00 PM EST
Knight Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Knight Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $10.83. The average 1-year stock price forecast is 16.20% higher than the current stock price, while the lowest is $9.00 (-3.43%) and the highest is $12.00 (+28.76%).
Price Target: $10.83 (+16.20%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Knight Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Nov '25 | Dec '25 | Feb '26 | Mar '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $9.50 → $11.00 | Buy | Maintains | $9.50 → $11.00 | +18.03% | Aug 7, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $9.50 → $11.00 | Buy | Maintains | $9.50 → $11.00 | +18.03% | Aug 7, 2026 |
| Bloom Burton | Bloom Burton | Buy Maintains $12.00 | Buy | Maintains | $12.00 | +28.76% | Aug 7, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Initiates $9.50 | Buy | Initiates | $9.50 | +1.93% | May 8, 2026 |
Financial Forecast
Revenue This Year
547.72M
from 450.09M
Increased by 21.69%
Revenue Next Year
546.30M
from 547.72M
Decreased by -0.26%
EPS This Year
0.22
from 0.02
Increased by 844.21%
EPS Next Year
0.26
from 0.22
Increased by 18.18%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CAD.